CDC20 and prostate carcinoma: Both SPOP mutation [61] and CDC20 overexpression are important in docetaxel resistance with the inhibition or knockdown of CDC20 being able to resensitise cells to docetaxel [62] highlighting the importance of CDC20 as a therapeutic target in prostate cancer at several disease stages.